A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA

CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks

CT-P13 (90 mg) by single SC injection every other week

CT-P13 (120 mg) by single SC injection every other week

CT-P13 (180 mg) by double SC 90 mg injections every other week

CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.

CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28